Please use this identifier to cite or link to this item:
Title: Doxycycline-rifampin versus doxycycline-rifampingentamicin in treatment of human brucellosis.
Authors: Bosilkovski, Mile 
Kirovska, Valerija
Grozdanovski, Krsto 
Vidinic, Ivan
Demiri, Ilir 
Labachevski, Nikola 
Issue Date: 2012
Publisher: SAGE Publications
Source: Mile B, Valerija K, Krsto G, Ivan V, Ilir D, Nikola L. Doxycycline-rifampin versus doxycycline-rifampingentamicin in treatment of human brucellosis. Trop Doct. 2012;42(1):13-7.
Journal: Tropical Doctor
Abstract: This prospective, non-randomized trial, compared the efficacy and tolerance of a doxycycline-rifampin regimen, administered for 45 days, versus doxycycline-rifampin given for 45 days plus gentamicin for the first 7-10 days, in the treatment of human brucellosis. Of 238 patients that were initially included in the study, 181 were finally evaluated. Ninety-four were treated with the doxycycline-rifampin and 87 with the doxycycline-rifampin-gentamicin regimens. In the doxycycline-rifampin group: relapses were noted in 13 (13.8%) patients; therapeutic failures in five (5.3%); and mild adverse effects in 28 (29.8%). In the doxycycline-rifampin-gentamicin group: four (4.6%) relapsed; and five (5.7%) therapeutic failures were registered. Mild adverse effects were registered in 29 (33.3%) patients. The doxycycline-rifampin-gentamicin regimen demonstrated a significantly lower relapse rate compared to the doxycycline-rifampin combination (P = 0.034). We conclude that adding gentamicin for the first 7-10 days to the standard oral doxycycline-rifampin regimen can decrease the rate of relapses.
Appears in Collections:Faculty of Medicine: Journal Articles

Show full item record

Page view(s)

checked on Sep 30, 2022

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.